{"id":3043,"date":"2026-08-30T14:13:05","date_gmt":"2026-08-30T14:13:05","guid":{"rendered":"https:\/\/liviagents.ai\/?p=3043"},"modified":"2026-08-30T14:13:07","modified_gmt":"2026-08-30T14:13:07","slug":"national-cancer-institute-early-stage-innovative-technology-development-r61","status":"publish","type":"post","link":"https:\/\/liviagents.ai\/index.php\/2026\/08\/30\/national-cancer-institute-early-stage-innovative-technology-development-r61\/","title":{"rendered":"National Cancer Institute: Early-Stage Innovative Technology Development (R61)"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">The National Cancer Institute (NCI) has announced a significant funding opportunity to accelerate the development of groundbreaking technologies in oncology. This grant is designed for novel capabilities in the cellular and molecular characterization of cancer, as well as improved handling of biospecimens.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Scope<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Part of the NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program, this R61 grant supports early-stage proof-of-concept and pilot studies. Funding covers up to $150,000 per year in direct costs for a maximum of three years.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Eligibility<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">This program offers broad eligibility, welcoming applications from public and private universities, nonprofits, for-profit businesses, and government entities. Foreign organizations and non-domestic entities are also fully eligible to apply.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Partnership<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The NCI strongly encourages partnerships between engineers, oncologists, and international collaborators. Bridging the gap between academic research and commercial development is key to translating technical expertise into cancer-relevant use cases.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">To successfully apply, projects must adhere to strict guidelines. Here are the core requirements:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Projects must focus on early-stage technical feasibility and validation.<\/li>\n\n\n\n<li>Applications must include clear numerical target performance measures (e.g., target sensitivity levels).<\/li>\n\n\n\n<li>Proposed technologies must be focused on cancer-relevant use cases.<\/li>\n\n\n\n<li>Clinical trials and purely hypothesis-driven research are excluded.<\/li>\n\n\n\n<li>Standalone software, data mining, or pure drug development without an innovative technology component will not be reviewed.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Deadline: November 10, 2026<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">More info: <a href=\"https:\/\/simpler.grants.gov\/opportunity\/00000220-55f5-4691-aec6-6eed51f77f2d\">https:\/\/simpler.grants.gov\/opportunity\/00000220-55f5-4691-aec6-6eed51f77f2d<\/a><\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\">Stay updated on the latest health tech funding:&nbsp;<a href=\"https:\/\/newsletter.livi.health\/signup\">https:\/\/newsletter.livi.health\/signup<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The National Cancer Institute (NCI) has announced a significant funding opportunity to accelerate the development of groundbreaking technologies in oncology. This grant is designed for novel capabilities in the cellular and molecular characterization of cancer, as well as improved handling of biospecimens. Scope Part of the NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program, this R61 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3044,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[23],"tags":[],"class_list":["post-3043","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-newsletter"],"_links":{"self":[{"href":"https:\/\/liviagents.ai\/index.php\/wp-json\/wp\/v2\/posts\/3043","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/liviagents.ai\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/liviagents.ai\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/liviagents.ai\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/liviagents.ai\/index.php\/wp-json\/wp\/v2\/comments?post=3043"}],"version-history":[{"count":1,"href":"https:\/\/liviagents.ai\/index.php\/wp-json\/wp\/v2\/posts\/3043\/revisions"}],"predecessor-version":[{"id":3045,"href":"https:\/\/liviagents.ai\/index.php\/wp-json\/wp\/v2\/posts\/3043\/revisions\/3045"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/liviagents.ai\/index.php\/wp-json\/wp\/v2\/media\/3044"}],"wp:attachment":[{"href":"https:\/\/liviagents.ai\/index.php\/wp-json\/wp\/v2\/media?parent=3043"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/liviagents.ai\/index.php\/wp-json\/wp\/v2\/categories?post=3043"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/liviagents.ai\/index.php\/wp-json\/wp\/v2\/tags?post=3043"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}